Skip to main content

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Advances in Therapy volume 37, pages 1145–1155 (2020)Cite this article

Abstract

Introduction

Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab.

Methods

This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treated with nivolumab in the second or later lines of therapy for at least four doses and with a disease re-staging.

Results

A total of 187 patients with available pretreatment laboratory results were included. NLR levels below 5 were associated with an improvement in terms of both progression-free survival (PFS) (p = 0.028) and overall survival (OS) (p = 0.001), but not in terms of overall response rate (ORR) or disease control rate (DCR). Moreover, PLR levels below 200 were associated with longer PFS (p = 0.0267) and OS (p = 0.05), as well as higher ORR (p = 0.04) and DCR (p = 0.001). In contrast, LDH levels above the upper normal limit (UNL) were not associated with significant impact on patient outcomes.

Conclusions

Patients with pretreated NSCLC and high pretreatment levels of NLR and PLR may experience inferior outcomes with nivolumab. Therefore, in this subgroup of patients with poor prognosis the use of alternative therapeutic strategies may be a valuable option, especially in programmed cell death ligand 1 (PD-L1)-negative patients and/or in the presence of other additional poor prognostic factors.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

AJCC:

American Joint Committee on Cancer

CR:

Complete response

DCR:

Disease control rate

dNLR:

Derived neutrophil-to-lymphocyte ratio

ECOG:

Eastern Cooperative Oncology Group

HR:

Hazard ratio

IHC:

Immunohistochemistry

iSEND:

Immunotherapy, sex, ECOG PS, neutrophil-to-lymphocyte ratio, and delta NLR model

LDH:

Lactate dehydrogenase

NLR:

Neutrophil-to-lymphocyte ratio

NSCLC:

Non-small cell lung cancer

ORR:

Overall response rate

OS:

Overall survival

PD-1:

Programmed cell death 1

PD-L1:

Programmed cell death ligand 1

PD:

Progressive disease

PFS:

Progression-free survival

PLR:

Platelet-to-lymphocyte ratio

PR:

Partial response

PS:

Performance status

Pts:

Patients

SD:

Stable disease

TNM:

Tumor, node, metastasis

UNL:

Upper normal limit

References

  1. Gridelli C, Ascierto PA, Grossi F, et al. Second-line treatment of advanced non-small cell lung cancer non-oncogene addicted: new treatment algorithm in the era of novel immunotherapy. Curr Clin Pharmacol. 2018;13:76–84.

    Article  CAS  Google Scholar 

  2. Russo A, Franchina T, Ricciardi GRR, et al. The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Crit Rev Oncol Hematol. 2018;130:1–12.

    Article  CAS  Google Scholar 

  3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.

    Article  CAS  Google Scholar 

  4. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.

    Article  CAS  Google Scholar 

  5. Ribas A, Hersey P, Middleton MR, et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012;18:336–41.

    Article  CAS  Google Scholar 

  6. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29:959–65.

    Article  CAS  Google Scholar 

  7. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

    Article  CAS  Google Scholar 

  8. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

    Article  CAS  Google Scholar 

  9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  Google Scholar 

  10. Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7.

    Article  Google Scholar 

  11. Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel. J Cell Physiol. 2018;233:6337–43.

    Article  CAS  Google Scholar 

  12. Ameratunga M, Chénard-Poirier M, Moreno Candilejo I, et al. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. Eur J Cancer. 2018;89:56–63.

    Article  CAS  Google Scholar 

  13. Fukui T, Okuma Y, Nakahara Y, et al. Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non-small-cell lung cancer: a prospective observational study. Clin Lung Cancer. 2019;20(208–214):e2.

    Google Scholar 

  14. Zer A, Sung MR, Walia P, et al. Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19(426–434):e1.

    Google Scholar 

  15. Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4:351–7.

    Article  Google Scholar 

  16. Tanizaki J, Haratani K, Hayashi H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13:97–105.

    Article  CAS  Google Scholar 

  17. Banna GL, Passiglia F, Colonese F, et al. Immune-checkpoint inhibitors in non-small cell lung cancer: a tool to improve patients’ selection. Crit Rev Oncol Hematol. 2018;129:27–39.

    Article  Google Scholar 

  18. Kargl J, Busch SE, Yang GHY, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381.

    Article  CAS  Google Scholar 

  19. Sagiv JY, Michaeli J, Assi S, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10:562–73.

    Article  CAS  Google Scholar 

  20. Christoffersson G, Phillipson M. The neutrophil: one cell on many missions or many cells with different agendas? Cell Tissue Res. 2018;371:415–23.

    Article  Google Scholar 

  21. Facchinetti F, Veneziani M, Buti S, et al. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy. 2018;10:681–94.

    Article  CAS  Google Scholar 

  22. Kiriu T, Yamamoto M, Nagano T, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018;13:e0193018.

    Article  Google Scholar 

  23. Nakaya A, Kurata T, Yoshioka H, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. 2018;23:634–40.

    Article  CAS  Google Scholar 

  24. Park W, Kwon D, Saravia D, et al. Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab. Clin Lung Cancer. 2018;19(280–288):e4.

    Google Scholar 

  25. Gu X, Sun S, Gao X-S, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3430 patients. Sci Rep. 2016;6:23893.

    Article  CAS  Google Scholar 

  26. Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81.

    Article  Google Scholar 

  27. Peters S, Cappuzzo F, Horn L, et al. OA03.05 analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab vs docetaxel in checkmate 057. J Thorac Oncol. 2017;12:S253.

    Article  Google Scholar 

Download references

Acknowledgements

Funding

The authors received no financial support for the research, authorship, and/or publication of this article. The journal’s Rapid Service Fee was funded by the authors.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions

Alessandro Russo, Marco Russano, Giuseppe Tonini, Daniele Santini, and Vincenzo Adamo contributed to the design of the study; Alessandro Russo, Marco Russano, Tindara Franchina, Maria R. Migliorino, Giuseppe Aprile, Giovanni Mansueto, Alfredo Berruti, Alfredo Falcone, Michele Aieta, Alain Gelibter, Sandro Barni, Michele Maio, Olga Martelli, Francesco Pantano, Daniela Iacono, Lorenzo Calvetti, Silvia Quadrini, Elisa Roca, Enrico Vasile, Marco Imperatori, Mario Occhipinti, Giulia Pasquini, Salvatore Intagliata, Giuseppina R. R. Ricciardi, Giuseppe Tonini, Daniele Santini, and Vincenzo Adamo contributed to the clinical management of patients and database, providing clinical, pathological and molecular data; Alessandro Russo, Marco Russano, Daniele Santini, Vincenzo Adamo performed data analysis and interpretation; Alessandro Russo, Marco Russano, Vincenzo Adamo, and Daniele Santini wrote the manuscript; all authors read and approved the final version of the manuscript.

Compliance with Ethics Guidelines

The trial protocol was previously approved by the Ethics Committee of the coordinating Center (Campus Bio-Medico University of Rome) on 2 March 2018 (approval n. 23/18 OSS ComEt CBM) and all the patients provided written informed consent before enrollment. The study was conducted in accordance with the Declaration of Helsinki.

Disclosures

All named authors (Alessandro Russo, Marco Russano, Tindara Franchina, Maria R Migliorino, Giuseppe Aprile, Giovanni Mansueto, Alfredo Berruti, Alfredo Falcone, Michele Aieta, Alain Gelibter, Antonio Russo, Sandro Barni, Michele Maio, Olga Martelli, Francesco Pantano, Daniela Iacono, Lorenzo Calvetti, Silvia Quadrini, Elisa Roca, Enrico Vasile, Marco Imperatori, Mario Occhipinti, Antonio Galvano, Fausto Petrelli, Luana Calabrò, Giulia Pasquini, Salvatore Intagliata, Giuseppina R.R. Ricciardi, Giuseppe Tonini, Daniele Santini, Vincenzo Adamo) have nothing to disclose.

Data Availability

The data that support the findings of this study are available from the corresponding author, Prof. Vincenzo Adamo, upon reasonable request.

Author information

Author notes

  1. Alessandro Russo and Marco Russano contributed equally to this work.

Authors and Affiliations

  1. Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina, Messina, Italy

    Alessandro Russo, Tindara Franchina, Giuseppina R. R. Ricciardi & Vincenzo Adamo

  2. Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy

    Marco Russano, Francesco Pantano, Giuseppe Tonini & Daniele Santini

  3. Pulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, Italy

    Maria R. Migliorino & Daniela Iacono

  4. Department of Oncology, San Bortolo General Hospital, Vicenza, Italy

    Giuseppe Aprile & Lorenzo Calvetti

  5. Medical Oncology Department, General Hospital, Frosinone, Italy

    Giovanni Mansueto & Silvia Quadrini

  6. Oncologia Medica, Azienda Ospedaliera Spedali Civili, Brescia, Italy

    Alfredo Berruti, Elisa Roca & Salvatore Intagliata

  7. Unit of Medical Oncology, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

    Alfredo Falcone, Enrico Vasile & Giulia Pasquini

  8. Division of Medical Oncology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero Vulture, PZ, Italy

    Michele Aieta & Marco Imperatori

  9. Division of Oncology, Department of Radiological, Oncological and Pathological Science, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy

    Alain Gelibter & Mario Occhipinti

  10. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy

    Antonio Russo & Antonio Galvano

  11. Medical Oncology Unit, ASST Bergamo Ovest, Treviglio, BG, Italy

    Sandro Barni & Fausto Petrelli

  12. Medical Oncology and Immunotherapy, Center for Immuno-oncology, University Hospital of Siena, Siena, Italy

    Michele Maio & Luana Calabrò

  13. Medical Oncology Unit, San Giovanni Addolorata Hospital, Rome, Italy

    Olga Martelli

Authors
  1. Alessandro Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Russano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tindara Franchina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria R. Migliorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Aprile
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanni Mansueto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alfredo Berruti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alfredo Falcone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michele Aieta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Alain Gelibter
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Antonio Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sandro Barni
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Michele Maio
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Olga Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Francesco Pantano
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Daniela Iacono
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Lorenzo Calvetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Silvia Quadrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Elisa Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Enrico Vasile
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Marco Imperatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mario Occhipinti
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Antonio Galvano
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Fausto Petrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Luana Calabrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Giulia Pasquini
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Salvatore Intagliata
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Giuseppina R. R. Ricciardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Giuseppe Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Daniele Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Vincenzo Adamo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Adamo.

Additional information

Enhanced Digital Features

To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.11550561.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Russo, A., Russano, M., Franchina, T. et al. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Adv Ther 37, 1145–1155 (2020). https://doi.org/10.1007/s12325-020-01229-w

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-020-01229-w

Keywords

  • LDH
  • Nivolumab
  • NLR
  • NSCLC
  • PD-1
  • PD-L1
  • PLR
  • Prognosis